GW Pharma’s rally rolls on as cannabinoid drug scores again in PhIII Epidiolex anti-convulsive study
GW Pharmaceuticals’ late-stage cannabinoid high is on a roll.
The UK biotech posted strong efficacy data for its experimental anti-convulsive therapy Epidiolex in treating Lennox-Gastaut syndrome, three months after getting the party started with a big rally on its pivotal data for Dravet syndrome, a rare form of severe epilepsy.
Investigators said their drug exactly doubled the 22% median reduction in drop seizures among a group of LGS patients with an average age of 15 — 44% vs 22%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
